Otsuka closes Astex acquisition despite last minute detractor
This article was originally published in Scrip
Otsuka Pharmaceutical has completed its acquisition of the cancer and CNS focused US firm Astex Pharmaceuticals following a successful tender offer, in a transaction valued at around $886m.
You may also be interested in...
Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.